Iovance Biotherapeutics, Inc. (IOVA) — SEC Filings
Iovance Biotherapeutics, Inc. (IOVA) — 50 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 29 8-K, 8 SC 13G/A, 6 10-Q.
View Iovance Biotherapeutics, Inc. on SEC EDGAR
Overview
Iovance Biotherapeutics, Inc. (IOVA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Iovance Biotherapeutics, Inc. reported a significant increase in product revenue, reaching $67.455 million for the three months ended September 30, 2025, up from $58.555 million in the prior year, representing a 15.2% increase. For the nine months, product revenue more than doubled to $176.731 milli
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 47 neutral, 3 mixed. The dominant filing sentiment for Iovance Biotherapeutics, Inc. is neutral.
Filing Type Overview
Iovance Biotherapeutics, Inc. (IOVA) has filed 6 10-Q, 29 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 1 DEFA14A, 1 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of IOVA's 41 recent filings, 2 were flagged as high-risk, 20 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $67.455M |
| Net Income | -$91.253M |
| Cash Position | $158.134M |
| Total Assets | $904.948M |
| Total Debt | $202.661M |
Key Executives
- Dr. Philip A. Pizzo
- Ms. Anne M. VanLent
- Dr. Frederick Vogt
- Dr. Elias K. Daniel
- Frederick G. Vogt
- Maria Fardis
- Raj K. Puri, M.D., Ph.D.
- Jean-Marc Bellemin
- Dr. Frederick "Fritz" Morgan
- Wayne P. Rothbaum
- Mark H. Rachesky, M.D.
Industry Context
Iovance Biotherapeutics operates in the highly competitive and rapidly evolving biopharmaceutical industry, focusing on cell therapies for cancer treatment. The sector is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Key trends include advancements in immunotherapy, personalized medicine, and the increasing demand for novel treatments for difficult-to-treat diseases.
Top Tags
biotech (6) · 8-k (5) · executive-compensation (5) · 8-K (5) · Biotechnology (4) · sec-filing (4) · financial-reporting (4) · board-of-directors (4) · 10-Q (4) · biotechnology (4)
Executive Compensation
From the most recent DEF 14A filing (Apr 29, 2024):
- Frederick G. Vogt — Member
- Maria Fardis — Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Revenue, Q3 2025 | $67.455M | Increased from $58.555M in Q3 2024, a 15.2% increase |
| Product Revenue, Nine Months 2025 | $176.731M | More than doubled from $90.376M in Nine Months 2024 |
| Net Loss, Q3 2025 | $91.253M | Widened from $83.541M in Q3 2024 |
| Net Loss, Nine Months 2025 | $319.074M | Increased from $293.618M in Nine Months 2024 |
| Restructuring Charges, Q3 2025 | $5.143M | Incurred due to restructuring plan announced in August 2025 |
| Cash and Cash Equivalents, Sep 30, 2025 | $158.134M | Increased from $115.694M at Dec 31, 2024 |
| Proceeds from Common Stock Issuance, Nine Months 2025 | $250.529M | Significant source of cash inflow |
| Research and Development Expenses, Q3 2025 | $75.174M | Increased from $67.036M in Q3 2024 |
| Common Stock Shares Outstanding, Sep 30, 2025 | 385,461,728 | Increased from 305,252,194 at Dec 31, 2024, indicating dilution |
| Net Loss | $120.5M | for the three months ended June 30, 2025, an increase from $105.2 million in Q2 2024 |
| Research and Development Expenses | $100.3M | for the three months ended June 30, 2025, up from $88.7 million in Q2 2024 |
| General and Administrative Expenses | $20.2M | for the three months ended June 30, 2025, up from $16.5 million in Q2 2024 |
| Cash and Cash Equivalents | $450.3M | as of June 30, 2025, providing liquidity for operations |
| Series B Preferred Stock | 333,934,387 | Value of Series B Preferred Stock as of March 31, 2025 |
| Fiscal Year End | 2024 | The filing covers compensation and governance for the fiscal year ending December 31, 2024. |
Forward-Looking Statements
- {"claim":"MHR Fund Management LLC will maintain a significant stake in Iovance Biotherapeutics, Inc. throughout 2024.","entity":"MHR Fund Management LLC","targetDate":"2024-12-31","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Iovance Biotherapeutics, Inc. (IOVA)?
Iovance Biotherapeutics, Inc. has 50 recent SEC filings from Jan 2024 to Nov 2025, including 29 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IOVA filings?
Across 50 filings, the sentiment breakdown is: 47 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Iovance Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Iovance Biotherapeutics, Inc. (IOVA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Iovance Biotherapeutics, Inc.?
Key financial highlights from Iovance Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IOVA?
The investment thesis for IOVA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Iovance Biotherapeutics, Inc.?
Key executives identified across Iovance Biotherapeutics, Inc.'s filings include Dr. Philip A. Pizzo, Ms. Anne M. VanLent, Dr. Frederick Vogt, Dr. Elias K. Daniel, Frederick G. Vogt and 6 others.
What are the main risk factors for Iovance Biotherapeutics, Inc. stock?
Of IOVA's 41 assessed filings, 2 were flagged high-risk, 20 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Iovance Biotherapeutics, Inc.?
Recent forward-looking statements from Iovance Biotherapeutics, Inc. include guidance on {"claim":"MHR Fund Management LLC will maintain a significant stake in Iovance Biotherapeutics, Inc. throughout 2024.",".